Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II

Photocure (OSE: PHO) said the FDA has published a proposed order in the Federal Register to initiate the process of reclassifying cystoscopic systems intended for bladder cancer use. The announcement is a favorable regulatory development, but the change is still at the proposed-order stage. Overall, near-term read-through for PHO appears modest given the lack of finalized reclassification details in the release.

Analysis

Photocure (OSE: PHO) said the FDA has published a proposed order in the Federal Register to initiate the process of reclassifying cystoscopic systems intended for bladder cancer use. The announcement is a favorable regulatory development, but the change is still at the proposed-order stage. Overall, near-term read-through for PHO appears modest given the lack of finalized reclassification details in the release.